The 58,000 sq m plant – Sanofi’s second factory in Singapore – will produce vaccines and other biopharmaceutical products ...

With more than 19 million start-ups created over the last three years, Hall said, “American entrepreneurs continue to step ...

Learn about the legal battle between Bristol Myers Squibb and the HHS over the 340B drug pricing program, as other drugmakers join in with rebate plans.

After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company ...

FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New Jersey. Adragos Pharma acquires Baccinex. Gelteq plans gel solution ...

The Down syndrome treatment market in the USA is valued at nearly $250 million, with companies like Aelis Farma, AC Immune, ...

Kronos is cutting 83% of its workforce, while Idorsia is considering cutting as many as 270 jobs. Elsewhere, PTC disclosed ...

法国制药公司赛诺菲在新加坡设立的新一代疫苗与生物医药制造设施正式落成。全数码化的设施可同时生产四种使用不同技术的疫苗和药物，有助于推动我国乃至亚洲的医疗发展。

Sanofi's $595m Singapore facility, Modulus, leverages advanced technology for rapid, flexible vaccine production, bolstering ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Bristol Myers Squibb has sued the Biden administration over payment terms for hospitals in the 340B Drug Discount Program.

The microbial therapeutic products market is forecast to grow from USD 17.11 billion in 2022 to USD 30.55 billion by 2030, ...